Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
B. Chen, K. Bromley-Brits, G. He, F. Cai, X. Zhang and W. Song
Pages 255-261 (7)
Cannabinoids have been shown to increase neurogenesis in adult brain, as well as protect neurons from excitotoxicity, calcium influx, inflammation, and ischemia. Recent studies have shown that synthetic cannabinoids can alleviate water maze impairments in rats treated with intracranial amyloid β protein (Aβ); however it is unknown whether this effect is due to the cannabinoids anti-inflammatory properties or whether it affects Aβ processing. Here we investigate whether cannabinoids have any effect on Alzheimers disease in vivo. We found that HU210, a potent synthetic cannabinoid, did not improve water maze performance or a contextual fear conditioning task in an APP23/PS45 double transgenic mouse model of AD. HU210 had no effect on APP processing and Aβ generation, as well as neuritic plaque formation in the brains of AD transgenic mice. Our study showed that synthetic cannabinoid HU210 had no beneficial effects on AD neuropathology and behavioral deficits of AD model mice, which advises caution of such drugs application in AD therapies.
Cannabinoids, HU210, memory deficits, Aβ, neurogenesis, Alzheimer
Townsend Family Laboratories, Department of Psychiatry, The University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.